For instance, MerTK has been shown to be a promising biomarker for predicting patient stratification with respect to HCC and a potential target to overcome resistance to anti-PD-1/PD-L1 therapy in HCC [20]. This evidence concerns the gene MERTK and hepatocellular carcinoma.